Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
In development
Guidance, NICE advice and quality standards
In development
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter (2 active)
Skip to results
Filter by title or keyword
Filter
Expected publication date
Expected publication date
From date
To date
Apply date filters
Area of interest
Area of interest
COVID-19 (6)
Type
(
1 selected
)
Type
Guidance (323)
Guidance programme
(
1 selected
)
Guidance programme
Clinical guidelines (28)
Diagnostics guidance (10)
Health technology evaluations (14)
Highly specialised technologies guidance (9)
Interventional procedures guidance (12)
Medical technologies guidance (11)
NICE guidelines (31)
Public health guidelines (1)
Technology appraisal guidance (323)
Apply filters
Showing 261 to 270 of 323
Sort by
Title
Date
Apply sorting
Type: Guidance
Remove Type: Guidance filter
Guidance programme: Technology appraisal guidance
Remove Guidance programme: Technology appraisal guidance filter
Guidance, NICE advice and quality standards in development
Title
Type
Expected publication date
Ruxolitinib for treating non-segmental vitiligo in people 12 years and over [ID3998]
Technology appraisal guidance
14 August 2024
Sacituzumab govitecan for treating advanced non-small-cell lung cancer after platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor [ID6375]
Technology appraisal guidance
TBC
Sacituzumab govitecan for treating hormone receptor-positive HER2-negative metastatic breast cancer after 2 or more therapies [ID4033]
Technology appraisal guidance
TBC
Sacituzumab govitecan for treating unresectable metastatic urothelial cancer [ID6150]
Technology appraisal guidance
TBC
Sebetralstat for treating acute attacks of hereditary angioedema in people aged 12 and over ID6284
Technology appraisal guidance
TBC
Secukinumab for treating enthesitis-related arthritis or juvenile psoriatic arthritis [ID3738]
Technology appraisal guidance
TBC
Selpercatinib for advanced thyroid cancer with RET alterations that has not been treated with systemic therapy [ID6132]
Technology appraisal guidance
25 September 2024
Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer (MA review of TA760) [ID6293]
Technology appraisal guidance
13 November 2024
Selpercatinib for treating RET fusion-positive advanced solid tumours in people aged 12 and over with no other treatment options [ID6273]
Technology appraisal guidance
TBC
Selpercatinib for untreated RET-positive advanced thyroid cancer [ID6183]
Technology appraisal guidance
TBC
Previous page
1
…
25
26
Current page
27
28
29
…
33
Page
27
of
33
Next page
Results per page
10
25
50
All
Back to top